` Comparison: MARKSANS vs ROG - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
Sign Up
Log in

MARKSANS
vs
ROG

Over the past 12 months, MARKSANS has underperformed ROG, delivering a return of -13% compared to the ROG's +3% growth.

Valuation Growth Profitability Solvency Stocks Performance
Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
MARKSANS
ROG
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
MARKSANS ROG
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

MARKSANS Intrinsic Value
173.38 INR
Undervaluation 5%
Intrinsic Value
Price
ROG Intrinsic Value
416.39 CHF
Undervaluation 23%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Marksans Pharma Ltd
NSE:MARKSANS
165.5 INR
Roche Holding AG
SIX:ROG
319.2 CHF
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
MARKSANS, ROG

MARKSANS
ROG
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Marksans Pharma Ltd
Revenue
Roche Holding AG
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
MARKSANS, ROG

MARKSANS
ROG
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Marksans Pharma Ltd
NSE:MARKSANS
Roche Holding AG
SIX:ROG
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

MARKSANS
56.8%
ROG
73.9%

Operating Margin

MARKSANS
15.5%
ROG
35%

Net Margin

MARKSANS
12.9%
ROG
20.9%

FCF Margin

MARKSANS
1.2%
ROG
17.7%

ROE

MARKSANS
14.5%
ROG
39.3%

ROA

MARKSANS
11.3%
ROG
12.7%

ROIC

MARKSANS
14.9%
ROG
19.4%

ROCE

MARKSANS
15.9%
ROG
29.2%

Solvency Comparison

Marksans Pharma Ltd
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
Roche Holding AG
Equity Waterfall
Assets
Liabilities
Equity
What is Equity Waterfall?
No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
MARKSANS, ROG

Loading
MARKSANS
ROG
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MARKSANS, ROG

Loading
MARKSANS
ROG
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
MARKSANS, ROG

Loading
MARKSANS
ROG
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare MARKSANS to other stocks
LLY
Eli Lilly and Co
More expensive
vs MARKSANS
JNJ
Johnson & Johnson
More expensive
vs MARKSANS
NOVN
Novartis AG
More expensive
vs MARKSANS
AZN
AstraZeneca PLC
More expensive
vs MARKSANS
Unlock Full Access to Alpha Spread
Create Free Account
ALPHA SPREAD
Follow us
Join more than 324,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett